Charles Harris
Endocrinology, Diabetes & Metabolism · Hawthorne, NYNPI 1578730586
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,703 of the $1,785 with a category attached, or 95.4%. Regeneron accounts for 61.3% of it on its own, with 2 other manufacturers making up the rest.
Across 8 payments — averaging $223.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1K
- Amgen$608
- Novo Nordisk$82
Across 1 payment — averaging $600,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$600K
What the payments were for
- Travel & lodging$1,70395%
- Food & beverage$825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 5 | $1,095 |
| Amgen | 2 | $608 |
| Novo Nordisk | 1 | $82 |
How this compares
$1,785 in reported general payments places this provider in the 55th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Other endocrinology, diabetes & metabolism in Hawthorne
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.